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Nucleotide excision repair and the long-patch mismatch repair systems correct abnormal DNA structures
arising from DNA damage and replication errors, respectively. DNA synthesis past a damaged base (transle-
sion replication) often causes misincorporation at the lesion site. In addition, mismatches are hot spots for
DNA damage because of increased susceptibility of unpaired bases to chemical modification. We call such a
DNA lesion, that is, a base damage superimposed on a mismatch, a compound lesion. To learn about the
processing of compound lesions by human cells, synthetic compound lesions containing UV photoproducts or
cisplatin 1,2-d(GpG) intrastrand cross-link and mismatch were tested for binding to the human mismatch
recognition complex hMutSa and for excision by the human excision nuclease. No functional overlap between
excision repair and mismatch repair was observed. The presence of a thymine dimer or a cisplatin diadduct in
the context of a G-T mismatch reduced the affinity of hMutSa for the mismatch. In contrast, the damaged
bases in these compound lesions were excised three- to fourfold faster than simple lesions by the human
excision nuclease, regardless of the presence of hMutSa in the reaction. These results provide a new perspec-
tive on how excision repair, a cellular defense system for maintaining genomic integrity, can fix mutations
under certain circumstances.
Mismatches in DNA resulting from replication errors, and
base damage caused by physical (UV light) and chemical (pol-
yaromatic hydrocarbons) agents, are responsible for the ma-
jority of human cancers (18). Although certain mismatches and
base lesions can be eliminated from DNA by the base excision
repair pathway initiated by glycosylases with narrow substrate
ranges, in human cells there exists a general mismatch repair
system and a general damage repair system of wide substrate
range. The mismatch repair system removes the mismatched
base as a nucleotide (44), and the excision repair system excises
the damaged base(s) in an oligonucleotide (52, 67).
The general mismatch repair system (long-patch mismatch
repair) corrects all eight single-base mismatches as well as
small insertion sequence loops with comparable efficiencies
(31, 44). The general nucleotide excision repair (excision re-
pair) system (8) not only is the sole repair pathway for bulky
lesions such as thymine dimers (T,.T) and cisplatin-guanine
adducts but also repairs a wide variety of nonbulky lesions such
as O6-methylguanine (O6-meG) at physiologically relevant
rates (52). Thus, it appears that both repair systems recognize
many dissimilar non-B DNA forms rather than a specific lesion
structure.
Given the wide substrate ranges of both systems, it is not
unreasonable to expect overlaps between the two substrate
spectra, or that one repair system may facilitate the function of
the other. Indeed, it has been shown that the excision repair
system recognizes mismatches and removes the mismatched
base in a manner identical to the removal of damaged bases
(27). Since a DNA lesion, by definition, changes the hydrogen-
bonding properties of the damaged base, all lesions can be
considered mismatches and potential substrates for binding
and processing by the general mismatch repair system. Fur-
thermore, DNA lesions such as pyrimidine dimers are often
miscoding during bypass DNA synthesis, giving rise to a lesion
in one strand and a mismatch in the other. These damaged
nucleotides superimposed on mismatches, which we call com-
pound lesions, are generated at significant levels in cells ex-
posed to DNA-damaging agents (18). Since compound lesions
are formally substrates for both repair systems, they may cause
the two systems either to act in concert or to compete in order
to restore the integrity of DNA.
There are several in vivo studies pertinent to the issues of
functional and mechanistic overlap between the two repair
systems. It has been reported that Escherichia coli uvrA mu-
tants have a normal mismatch correction function, and hence
it was concluded the excision repair system did not play a role
in mismatch correction carried out by the methyl-directed mis-
match repair system (10). In contrast, several lines of evidence
have implicated the long-patch mismatch repair in processing
of UV damage both in E. coli and in humans. In E. coli, it was
found that recombinogenic rescue of UV-irradiated lambda
phage was dependent on uvrA, -B, and -C genes (excision
repair) as well as on functional mutL and mutS genes (mis-
match repair), suggesting that the two systems acted in a co-
ordinated manner to generate a prerecombinogenic substrate
(14, 15). Both in E. coli and in humans, mutations in mutS
(hMSH2 in humans) andmutL (hPMS2 in humans) were found
to render cells slightly sensitive to UV and to abolish the
transcription repair coupling of the template strand (40, 41) in
an actively transcribing gene. Finally, both E. coli (16) and
human (11) mismatch repair mutants have been found to have
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increased resistance to killing by cisplatin. These last findings
suggest that in contrast to UV damage, the cisplatin lesions are
recognized but cannot be eliminated by the mismatch repair
system, leading to a futile and lethal cycle of excision and
resynthesis which is known to occur with O6meG-T lesions (4,
28). Indeed, it was found that the human mismatch recognition
complex hMutSa (hMSH2-GTBP heterodimer) binds to G-T,
O6meG-T, and cisplatin-1,2-d(GpG) lesions with comparable
efficiencies (13) and that hMSH2 binds to cisplatin-1,2-d
(GpG) with high affinity (39).
While these are compelling data for functional overlap be-
tween excision repair and mismatch repair, there are several
observations which are inconsistent with such a model. First, a
study with strains of human mismatch repair mutants different
from those used for strand-specific repair found that these
mutants had normal UV resistance (2). Second, Saccharomyces
cerevisiae has mismatch and excision repair systems which are
structurally and functionally very similar to the human repair
systems (18, 21, 31, 44). Interestingly, abolishing the yeast
mismatch repair by mutations inmutS andmutL homologs had
no detectable effect on UV survival or transcription-coupled
excision repair of pyrimidine dimers in vivo (59), indicating
that mismatch repair and excision repair are independent of
each other. Finally, cell extracts (CEs) of E. coli mutS and
mutL mutant strains carry out transcription-coupled excision
repair in vitro, and the rate of transcription-stimulated repair is
not affected by supplementing a mutS mutant CE with purified
MutS protein (54).
We wished to address the issue of excision repair/mismatch
repair connection in humans directly by conducting in vitro
experiments. Using mutant CEs, the human excision repair
system reconstituted from purified proteins, and the purified
hMutSa protein, we investigated the processing of the two
major UV photoproducts, the cyclobutane thymine dimer
(T,.T) and (6-4) photoproduct (T[6-4]T), and the major
adduct of the anticancer drug cisplatin, the 1,2-d(GpG) intras-
trand cisplatin cross-link (34). The results show that the human
long-patch mismatch repair system does not influence the re-
pair of these lesions by human excision nuclease.
MATERIALS AND METHODS
Cell strains and repair factors. HeLa and HEC-1-A cell strains were from the
stock of the Lineberger Cancer Center Tissue Culture Facility (University of
North Carolina). The LoVo cell line (CCL-229) was purchased from American
Type Culture Collection (Rockville, Md.). Whole-cell extracts were prepared by
the method of Manley et al. (36), and nuclear extracts were prepared as de-
scribed by Holmes et al. (24). The whole-cell extracts were used for the exper-
iments reported unless indicated otherwise. The hMutSa heterodimer (12),
hMutLa (33), and the six factors of human excision nuclease (45) were purified
as described previously.
Incision/excision assays. Duplexes of 136 or 140 bp containing DNA damage,
mismatches, or both were prepared from six partially complementary oligomers
as described previously (26, 37). Table 1 shows the sequences of the 21 oligo-
nucleotides used in this study. Oligonucleotides containing T,.T and T[6-4]T
were prepared by the method of Smith and Taylor (56). The cisplatin-modified
oligonucleotide was prepared as described by Zamble et al. (68). These modified
oligomers, with the exception of oligomer 8 (provided by J.-S. Taylor), were a
kind gift from X. Zhao. The unmodified oligonucleotides were purchased from
Operon Biotechnology (Alameda, Calif.). To directly compare the incision and
excision products of T,.T and T[6-4]T substrates, 136-mer duplex DNAs of the
same sequence were constituted as shown in Fig. 1A. For determining the
incision sites, oligonucleotide 1 was terminally labeled with [g-32P]-ATP (NEN-
Dupont) and T4 polynucleotide kinase. For analyzing the excision products, the
damage-containing oligomer was 59-terminally labeled in the same manner. The
labeled oligomers were ligated with the other five oligonucleotides to obtain
either 59-terminally labeled or internally labeled duplexes as described previously
(26, 37). The full-length duplexes were separated from partially ligated products
by sequential purifications through 8% denaturing and 5% nondenaturing poly-
acrylamide gels. The concentrations of substrates are given in terms of duplex
DNA and were calculated from the specific activity (7,000 Ci/mmol) of
[g-32P]ATP used in phosphorylating the appropriate oligomers.
The incision/excision assays were carried out as described previously (37, 45,
46). The reactions with the reconstituted human excision nuclease (45, 46) were
done with mixtures contained 20 ng of XPA, 2 ng of TFIIH, 8 ng of XPC, 4 ng
of XPF-ERCC1, 20 ng of XPG, 250 ng of replication protein A (RPA), and 25
fmol of substrate in 25 ml of excision buffer. The reaction times, unless indicated
otherwise, were 2 h for the reconstituted excision nuclease and 1 h for reactions
with CEs. The reaction products were separated on 8% denaturing polyacryl-
amide gels and visualized by autoradiography, and the excision products were
quantified with a PhosphorImager (Molecular Dynamics, Inc.).
S1 nuclease digestion. Fifteen femtomoles of internally labeled substrate
[T,.T(0), T,.T(1), T,.T(2), or T,.T(4)] was incubated at room temper-
ature for 25 min with 0.5 U of S1 nuclease (Gibco BRL/Life Technologies) in 15
ml of reaction mixture containing 30 mM sodium acetate (pH 4.6), 1 mM zinc
acetate, 150 mM NaCl, 5% glycerol, and ;1 nM substrate. The reaction was
stopped by addition of formamide-dye, and the products were analyzed on an 8%
denaturing polyacrylamide gel.
TABLE 1. Oligonucleotides used to assemble the substrate DNAs






















a Contains an intrastrand cis-platinated diadduct at the two guanidine [G*G*].
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Gel retardation assay. The reaction conditions were adapted from those of
Duckett et al. (13). Briefly, the binding reaction mixture contained (in 15 ml) 10
mMHEPES-KOH (pH 7.6), 100 mM KCl, 5 mMMgCl2, 1 mM dithiothreitol, 50
mg of bovine serum albumin per ml, 200 fmol of unlabeled duplex 31-mer (made
from oligonucleotides 16 and 17 [Table 1]), 8 fmol of internally labeled probe,
and the indicated amounts of hMutSa. The mixture was incubated for 15 min at
room temperature, then 3 ml of 80% glycerol was added, and the DNA-protein
complexes were resolved on 5% nondenaturing polyacrylamide gels running in
20 mM Tris-acetate (pH 7.6)–1 mM MgCl2 at 8 V/cm and room temperature
with buffer circulation (1 liter/h). The retarded DNA was quantified with a
PhosphorImager, assuming that all DNA migrating more slowly than the free
DNA band in the control lane was retarded by the protein.
RESULTS
Substrates and incision/excision. We constructed 136- to
140-bp substrates by ligating partially overlapping oligonucle-
otides with a modified oligomer containing a DNA lesion in a
predetermined position. Table 1 lists the oligonucleotides used
in this study. The substrates were either terminally (59) or
internally (4th or 13th phosphate 59 to the lesion) labeled for
the purpose of analysis of the reaction products of human
excision nuclease. Figure 1 shows the results of such an analysis
with substrates containing T,.T and T[6-4]T photoproducts.
Both lesions are good substrates for the reconstituted excision
nuclease, and both are removed by dual incisions (25), mainly
in 24- to 28-nucleotide (nt)-long oligomers (lanes 6 and 8), by
incisions of phosphodiester bonds 16 to 26 (Fig. 1A and B,
lanes 7 and 9) and phosphodiester bonds 3 to 7 39 to the
photodimer, with the incisions at the 19th and 20th and at the
23rd and 24th phosphodiester bonds 59 and the 6th and 7th
phosphodiester bonds 39 to the lesion being the predominant
ones. Quantitative analyses of the excision data in lanes 6 and
8 of Fig. 1B and of several experiments conducted under iden-
tical conditions reveal that the T[6-4]T photolesion is repaired
threefold faster than the T,.T photoproduct, in agreement
with the relative rates of removal of these lesions in vivo (42,
43). The excision rate and pattern of cisplatin 1,2-d(GpG)
cross-link are comparable to those of T[6-4]T and have been
reported previously (27, 68).
Binding of hMutSa to damage, mismatch, and compound
lesions. According to current models for mismatch repair (31,
44), the binding of hMutSa to the mismatch is an early if not
the earliest step in repair of simple single-base mismatches.
Hence, to learn if there is a functional overlap between mis-
FIG. 1. Incision/excision of T,.T and T[6-4]T photoproducts by human excision repair nuclease. (A) Substrates and incision sites. a, the substrates were
constructed by ligating the indicated six oligonucleotides. The resulting 136-bp duplexes were of the same sequence except for one containing T,.T and another
containing T[6-4]T at positions 68 and 69. For incision assays 1 oligomer 1, and for excision assays oligomer 2 or 3, was 59 phosphorylated with 32P before annealing
and ligation with the other oligomers. b, sequence around the photolesions and incision sites of human excision nuclease. The 59 incision sites were determined from
panel B and from other gels where the Maxam-Gilbert sequence ladder were run alongside the incision lanes. With 59-labeled substrates, the 39 incision sites can be
seen only when they are uncoupled from the 59 incisions, and the major uncoupled incisions may not be the same as the major 39 coupled incisions. The major 59 and
39 (uncoupled) incisions were identical for the two photoproducts. The 23rd phosphodiester bond 59 and the 6th phosphodiester bond were the major sites. There was
very little incision at the 22nd and 21st phosphodiester bonds. The major excision products were 25 to 28 nt in length. Examples of how they can be generated by
combination of 39 and 59 incisions are indicated. Note that the sequence of the T,.T-containing oligomer (oligomer 3) used in this experiment is different from that
of oligomer 8 used for other experiments in this study. (B) Incision/excision assays. Internally labeled (I) or 59-end-labeled (E) fragments were subjected to the indicated
treatments and then separated on an 8% denaturing polyacrylamide gel. Lanes 1 to 4 contained substrates with no enzymatic treatment. Note that the T[6-4]T substrate
contains a minor contaminant which terminates immediately 39 to the photolesion, as evidenced by the treatment of this substrate with T4 DNA polymerase 39 to 59
exonuclease (which is blocked by the photolesion generating a fragment that marks the 39 side of the lesion) (data not shown). Lanes 6 to 8, the indicated DNAs treated
with reconstituted excision nuclease for 2 h at 308C. Lane 5 contains size markers; the sizes are indicated in nucleotides in lane 10.
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match repair and damage repair, we constructed the substrates
shown in Fig. 2 and tested the binding of hMutSa to UV
photoproducts and cisplatin-1,2-d(GpG) intrastrand cross-link
in the normal sequence context and in the form of compound
lesions. Figure 3 shows that DNA containing T,.T or T[6-
4]T has marginal affinity for hMutSa compared to the normal
duplex. In contrast, cisplatin-1,2-d(GpG) cross-link binds to
hMutSa with a higher affinity as reported previously (13). Of
special significance, compound lesions of both UV photoprod-
ucts and the cisplatin diadduct in the context of a G-T mis-
match were bound by hMutSa with about twofold-lower affin-
ity than that of a simple G-T mismatch, suggesting that a G-T
mismatch in a compound lesion is less susceptible to mismatch
correction (Fig. 3C).
Effect of mismatch repair system on excision repair. The
data presented so far indicate that DNA damage is recognized
with various degrees of affinities by the mismatch repair sys-
tem. In combination with the various in vivo reports on dimin-
ished damage repair in mismatch repair mutants (41), this
finding raised the possibility that mismatch repair proteins
directly participate in excision repair. To test for this, we con-
ducted excision repair assays with mismatch mutant CEs, using
DNA with damaged bases in the normal sequence context as
well as in compound lesions. The results obtained with the
T,.T substrate are shown in Fig. 4A. With a simple T,.T
lesion, it appears that HeLa CE is more efficient than CE from
either an hPMS2 mutant (MutL homolog) or an hMSH2 mu-
tant (lanes 2 to 4). However, the excision efficiencies of extracts
FIG. 2. Substrates for mismatch binding and excision experiments. (A) Sub-
strate assembly strategy. All substrates were internally labeled by using Y oli-
gomer that had been phosphorylated with [g-32P]ATP. (B) Schematic presenta-
tion of the various substrate and control duplexes used in the study.
FIG. 3. Binding of hMutSa to DNA damages as simple or compound lesions,
as tested by a gel retardation assay. (A) Binding to photoproducts. Reaction
mixtures contained 1 nM the indicated substrate and 0, 6.3, 9.5, or 19 nM
hMutSa. The G-T mismatch substrate used in lanes 17 to 20 was generated by
photoreactivation of the compound lesion used in lanes 9 to 12, using E. coli
photolyase. (B) Binding of hMutSa to cisplatin 1,2-d(GpG) simple and com-
pound lesions. Reaction mixtures contained 1 nM the appropriate substrate and
0, 9.5, or 19 nM hMutSa. (C) Quantitative expression of the binding data.
Binding data with 9.5 nM hMutSa from the experiments in panel A and two
other experiments conducted under identical conditions and from panel B and a
second experiment conducted under identical conditions are shown. All data
have been normalized to the binding of the corresponding normal homodu-
plexes. Bars indicate standard errors. Note that the simple G-T mismatch sub-
strate was generated by splitting the T,.T in the corresponding compound lesion.
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are highly dependent on the cell lines (49), and hence this
difference cannot be attributed simply to the difference in the
mismatch repair status in the absence of complementary data.
Such data can be obtained by complementation experiments
with mutant CE. We initially carried out these experiments
with a simple T,.T lesion and saw no complementation (data
not shown). However, since hMutSa binds only weakly to a
simple T,.T but with higher affinity to a T,.T with a G-T
mismatch, we reasoned that we would be more likely to see the
stimulatory effect of mismatch repair system on excision repair
with this compound lesion substrate. Figure 4A (lanes 5 to 10)
shows the results of these experiments. Two points are note-
worthy. First, the T,.T compound lesion was excised twofold
more efficiently by HeLa CE than a T,.T simple lesion (com-
pare lanes 2 and 6). This finding raised the possibility that the
high-affinity binding of hMutSa to the T,.T compound le-
sion might contribute to more efficient repair by aiding in
damage recognition. However, the same level of stimulation
was observed with CEs from the hPMS2 mutant HEC-1-A (50)
(compare lane 3 with lane 7) and the hMSH2 mutant LoVo
(66) (compare lane 4 with lane 8), revealing that a T,.T
compound lesion is a better substrate than a T,.T simple
lesion regardless of the cell’s mismatch repair status. Second,
complementation assays with HEC-1-A and LoVo CEs (lanes
9 and 10) failed to improve the excision activity above that seen
with HEC-1-A CE alone, again suggesting that the mismatch
repair system plays no role in damage excision from either
simple or compound T,.T lesions.
When the same experiments were performed with a T[6-4]T
substrate, essentially the same results were obtained but with
two important differences (Fig. 4B). First, under identical con-
ditions, the T[6-4]T lesion was excised threefold more effi-
ciently than a T,.T lesion across the board, in agreement
with data in Fig. 1 showing that T[6-4]T is the better substrate.
Second, in contrast with the drastic effect of a mismatch on the
excision rate of a T,.T lesion, the rates of excision of T[6-4]T
lesion from a normal duplex and a complex lesion are identical
in CE (Fig. 4B) and in reconstituted excision nuclease (see Fig.
6). From the point of view of mismatch repair and excision
repair overlap, however, the results with T[6-4]T completely
parallel those obtained with T,.T; namely, CEs from mis-
match repair mutants carry out excision repair efficiently, and
mixing of CEs from two different complementation groups of
mismatch repair did not improve the efficiency of damage
excision (Fig. 4B; compare lanes 7 and 8 with lanes 9 and 10).
Effect of hMutSa and hMutLa on excision repair. Experi-
ments with cisplatin-1,2-d(GpG) diadduct and CEs gave re-
sults more similar to those obtained with the T,.T substrate.
However, in light of known affinity of hMutSa for the cisplatin
adduct (13) (Fig. 3), we decided to conduct experiments by
adding purified hMutSa or hMutLa to either mutant (LoVo
and H6) CE or the excision nuclease reconstituted from puri-
fied proteins (45, 46). The results of the experiments with CEs
are summarized in Fig. 5. Clearly, hMutSa does not affect the
efficiency of excision of compound T,.T or cisplatin lesion by
the LoVo CE (lanes 1 to 5). Likewise, hMutLa did not com-
FIG. 4. Effect of the mismatch repair system on excision of UV photoproducts from simple and compound lesions. The excision reactions were carried out with
CEs for 60 min at 308C. The amounts of CEs used were 108 mg for HeLa, 56 mg for HEC-1-A (50), and 84 mg for LoVo (66). These amounts were empirically found
to be optimal for individual CEs. In the complementation assays, in each panel, lane 9 contained 38 mg of HEC-1-A and 28 mg of LoVo CEs, and lane 10 contained
21 mg of HEC-1-A and 56 mg of LoVo CEs. (A) Excision assay with 140-bp duplexes containing T,.T. The levels of excision as percentages of the input substrates
(25 fmol) were as follows: lane 1, not detectable; lane 2, 2.5; lane 3, 1.9; lane 4, 1.7; lane 5, not detectable; lane 6, 5.2; lane 7, 4.3; lane 8, 4.1; lane 9, 4.1; and lane 10,
3.8. (B) Excision assay with 136-bp duplexes (25 fmol) containing T[6-4]T. The levels (percentages) of excision were as follows: lane 1, not detectable; lane 2, 8.2; lane
3, 8.8; lane 4, 7.1; lane 5, not detectable; lane 6, 8.1; lane 7, 9.0; lane 8, 6.1; lane 9, 6.5; and lane 10, 6.9. Sizes are indicated in nucleotides.
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plement the excision nuclease activity in H6 CE, which is
defective in the MLH1 mismatch repair factor (31, 44) (lanes
6, 7, 9, and 10). Furthermore, Fig. 5 (lanes 6 to 11) shows that
the H6 extract is active in excision repair of both thymine
dimer and cisplatin. Although the H6 CE seemed to be less
active than HeLa CE, the excision activity of H6 CE was not
affected by supplementing the extract with hMutLa, reinforc-
ing the conclusion that in a cell-free system, the presence or
lack of mismatch repair activity has no effect on excision repair.
To eliminate any uncertainty arising from our use of the
rather ill-defined CE excision repair system, we repeated the
experiments with the purified excision nuclease. The experi-
ments were conducted with the compound lesion in the pres-
ence or absence of hMutSa and quantified. As shown in Fig. 6,
like a T,.T and unlike a T[6-4]T compound, cisplatin 1,2-
d(GpG) diadduct is removed with about twofold-higher effi-
ciency than the simple lesion (compare lanes 1 and 3), regard-
less of the presence of hMutSa (lanes 2 and 4). Taken together
with the data for CEs, our results suggest that mismatch repair
proteins do not participate in or otherwise influence the dam-
age removal carried out by human excision nuclease in vitro.
Effect of multiple mismatches on excision repair. The T[6-
4]T lesion, which is the most efficiently excised damage of the
three substrates tested in this study, breaks the hydrogen bonds
of the two bases which make up the photoproduct (30, 62). In
contrast, T,.T and cisplatin 1,2-d(GpG) distort the helix, but
neither T,.T (29, 30, 63) nor cisplatin 1,2-d(GpG) intras-
trand cross-link (61) disrupts the hydrogen bonds of the mod-
ified bases. Interestingly, breaking the hydrogen bonds of one
base of the latter two lesions greatly stimulated their rates of
removal, but introduction of a mismatch across from T[6-4]T
had no effect on its rate of repair (Fig. 4B and 6). Since a
bubble generated by the TFIIH helicase function of human
excision nuclease is presumed to be an intermediate in the
reaction pathway of this enzyme system (52, 67), we reasoned
that introducing more mismatches around the lesion may fa-
cilitate the preincision complex formation and perhaps obviate
the need for some of the excision nuclease factors or further
increase the rate of excision.
We constructed T,.T substrates with one, two, or four
mismatches 59 to the T,.T as shown in Fig. 7. The mis-
matches were introduced on the 59 side because the preincision
bubble is hypothesized to extend to the 59 incision site of the
excision nuclease, which is 17 to 24 nt 59 to the lesion site (Fig.
2). The substrates were tested for single strandedness by di-
gestion with S1 nuclease (Fig. 7A). By this probe, the T,.T
with two mismatches gave a weak signal (not visible in this
reproduction); however, the lesion with four mismatches ap-
peared to be single stranded over the entire length of the
mismatch (Fig. 7A, lane 10). Attempts to accomplish excision
with this substrate containing four mismatches [T,.T(4)] by
omitting some of the repair factors failed. Indeed, even a
further enlargement to a 10-nt bubble with T,.T(4) did not
obviate the need of TFIIH for damage excision (46a). This is in
contrast to the role of TFIIH in transcription, where a 12-bp
mismatch upstream of the transcription initiation site elimi-
nated the need for TFIIH in transcription by RNA polymerase
II (47).
Even though a single mismatch improved the excision effi-
ciency by a factor of 2 to 4 in CE and reconstituted excision
nuclease (Fig. 7B; compare lanes 1 and 5 with lanes 2 and 6),
two mismatches did not improve it any further. In fact, four
mismatches reduced the repair signal slightly compared to the
single mismatch (compare lanes 2 and 4 and lanes 6 and 8).
The fact that similar trends of excision efficiency were observed
with both the CE and the purified excision nuclease suggests
that bubble-binding proteins which may be present in the CE
do not affect excision repair. This is particularly relevant to the
question of mismatch repair/excision repair overlap because of
the presence in human cells of an hMutSb (hMSH2-hMSH3)
mismatch recognition complex with high affinity for loop struc-
tures (11a).
Excision of T<>T associated with either a 5* or 3* T-G
mismatch. The results presented so far suggest that compound
lesions are more mutagenic than simple lesions because they
are removed more efficiently by excision repair and recognized
less efficiently by the mismatch repair system. Most cisplatin-
caused mutations at GG sequences are G-C to A-T transitions
at the 59 guanine (3, 6), consistent with our use of a G-T
mismatch in the cisplatin 1,2-d(GpG) compound lesion (Fig.
2). However, most of the UV-induced mutations at TT se-
quences are T-A-to-C-G transitions at the 39 T-A base pair (19,
32). Therefore, in addition to the 59 T-G mismatches in our
T,.T compound lesions, we wished to use 39 T-G-associated
compound lesions to ascertain that the preferential repair of
compound T,.T lesions contributes to UV mutagenesis. Fig-
ure 8 shows the rates of T,.T removal from 59 T-G and 39
T-G compound lesions. As is apparent, the mismatch has the
FIG. 6. Effect of hMutSa on the damage excision activity of reconstituted
human excision repair nuclease. To the reaction mixture containing 1 nM the
indicated substrate (25 fmol) and reconstituted human excision nuclease (46), 19
nM hMutSa was added (lanes 2, 4, and 8). cis Pt, cisplatin.
FIG. 5. Effects of hMutSa and hMutLa on excision of T,.T or cisplatin
1,2-d(GpG) [cis Pt(1)] from a compound lesion by CEs of mismatch repair
mutants. The experiments were conducted as described for Fig. 4, and the level
of excision was quantified with a PhosphorImager. Lane 2 contained 6.3 nM
hMutSa; lanes 3 and 5 contained 19 nM hMutSa. Bars indicate standard errors.
Fifty nanograms of hMutLa was present in lanes 7 and 10. Lanes 6, 7, 9, and 10,
excision reactions with H6 CE only; lanes 8 and 11, reactions with HeLa CE only.
The H6 nuclear extract was prepared by a procedure developed for measuring
mismatch repair activity (24).
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same stimulatory effect regardless of whether it is across from
the 39 T or the 59 T of the photodimer. Thus, the most com-
monly occurring compound lesion, G-T mismatch across from
the 39 T of the T,.T, also stimulates the T,.T excision, and
this rapid rate of damage removal may contribute to the dif-
ferences in UV mutation spectra of repair-proficient and re-
pair-deficient human cell lines.
DISCUSSION
Interfacing of mismatch and excision repair systems. There
is no genetic evidence linking excision repair to mismatch
correction; in contrast, several in vivo studies both in E. coli
and in humans have implicated the mismatch repair system in
DNA damage repair, in particular in the processing of bulky
DNA lesions which can be removed from DNA only by nucle-
otide excision repair (44). Curiously, it appears that lack of
mismatch repair has opposite effects on the cellular response
to two DNA-damaging agents, UV and cisplatin. Mismatch
repair-defective mutants are sensitive to UV (38, 40, 41) and
are deficient in transcription-coupled excision repair of cy-
clobutane pyrimidine dimers (40, 41). In contrast, mutations in
the mutL gene in E. coli (16) and the hMLH1 (a mutL ho-
molog) gene in humans confer increased resistance to cisplatin
(1, 11).
These findings raise two questions: does mismatch repair
eliminate bulky lesions from DNA, and why does the mismatch
repair defect have opposite effects on lethalities of the two
types of agents which cause bulky lesions? The answer to the
first question is that the removal of both cyclobutane dimers
(the major UV photoproduct) and of cisplatin 1,2-d(GpG)
intrastrand cross-link (the major lesion of cisplatin) is abso-
lutely dependent on excision repair (18), and human excision
nuclease capable of removing these lesions at near-physiolog-
ical rates has been reconstituted from purified proteins in the
absence of any mismatch repair protein (45, 68). Hence, if the
mismatch repair system plays any role in damage excision re-
pair, it can exert a stimulatory effect only on the basal excision
activity. However, we did not detect any effect of hMutSa on
excision of T,.T or cisplatin in either sequence context by
whole CE or excision nuclease reconstituted from purified
proteins. Thus, our data do not support a model which involves
joint actions of mismatch and excision repair systems to elim-
inate UV photoproducts from DNA.
Regarding the opposite effects of mismatch repair defect on
cellular resistance to UV and cisplatin, it is of special relevance
that hMutSa can bind to cisplatin 1,2-d(GpG) (13). Such bind-
ing may lead to death rather than survival. The discovery of
genetic defects in the GTBP/p160 subunit of MutSa in cell
lines selected for resistance to N-methyl-N9-nitro-N-nitroso-
guanidine (4, 20, 28) has led to the suggestion that the mis-
match repair system plays a role as a sensor of genetic damage
in the general sense, that is, as a sensor of structural anomalies
whether they arise from base mismatch or base damage (23,
28). Furthermore, it has been suggested that a signaling reac-
tion initiated by such an interaction could lead to cell death by
either a futile excision and resynthesis reaction provoked by
the damage or by somehow activating an apoptotic response
(1, 11). Whatever the mechanism, in this study we found no
FIG. 7. Effect of the number of mismatches in a compound lesion on the removal efficiency of T,.T by human excision nuclease. (A) Probing for mismatch-
induced single strandedness by S1 nuclease. Lanes 1 and 4 contained DNA size markers; lanes 2 to 5 and 7 to 10 contained substrates with the indicated number of
mismatches without and with S1 nuclease digestion, respectively (see Fig. 2 for substrate constructs). (B) Excision of T,.T associated with zero to four mismatches
by HeLa CE (lanes 1 to 4) and reconstituted human excision nuclease (lanes 5 to 8). The percentages of T,.T excised were as follows: lane 1, 1.9; lane 2, 4.2; lane
3, 4.4; lane 4, 4.0; lane 5, 2.3; lane 6, 9.4; lane 7, 9.6; and lane 8, 9.4. Sizes are indicated in nucleotides.
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supporting evidence for the interfacing of mismatch repair and
excision repair systems as a cause of cisplatin cytotoxicity.
It must be noted, however, that this study focused on exci-
sion repair in the absence of transcription. It has been reported
that mutations inmutL andmutS in E. coli (40) and the human
homologs of these genes (41) abolish transcription-coupled
repair. Currently, there is no in vitro system for eucaryotic
transcription-coupled excision repair, and hence this issue re-
mains for future investigations (22). However, there are sev-
eral observations which are relevant to the question. First, the
E. coli transcription-coupled excision repair system has been
reconstituted with purified proteins in vitro and is independent
of mismatch repair proteins (53). In addition, CEs from E. coli
mutL and mutS mutants are capable of performing transcrip-
tion-coupled repair, and the addition of purified MutS protein
to the mutS CE had no effect on the level of transcription-
repair coupling (54). It has been found that in the yeast S.
cerevisiae, whose mismatch repair and excision repair systems
are structurally and functionally highly similar to the human
repair systems (21, 31, 48), mutations in mismatch repair genes
did not affect the preferential removal of T,.T from the
transcribed strand (59). Thus, in light of currently available
data, it is more likely that the mismatch repair system does not
directly participate in coupling of excision repair to transcrip-
tion. Perhaps the drastic effect of mismatch repair defect on
DNA metabolism interferes with coupling by yet undiscovered
mechanisms.
Mutagenic excision repair and mutation fixation. UV mu-
tagenesis has been classified as type I or type II, depending on
requirement for excision repair (35). Type I is dependent on
replication and is presumed to result from translesion synthe-
sis. Type II is dependent on excision repair. It can occur even
in the absence of replication and is presumed to result from
misincorporation by bypass synthesis during filling in of an
excision gap in which the template strand contains a UV pho-
toproduct. Recent in vitro studies have provided evidence that
a significant fraction of UV-induced mutations may arise from
type II mutagenesis (9, 65). Although this classification was
originally made for UV-induced mutations in E. coli, evidence
exists that damage-induced mutations may occur by similar
mechanisms in humans (51). Here we show that excision repair
of compound T,.T lesions may contribute to mutagenesis by
these photoproducts.
Thymine cyclobutane dimer (T,.T), compared to T[6-4]T,
is a notoriously poor substrate for excision repair (42, 58, 60).
Unlike T[6-4]T, the cyclobutane dimer is also a poor replica-
tional block (7, 57, 64), allowing translesion replication with
occasional misincorporation (62). Even though the misincor-
poration frequency is low (19, 57), it is expected that com-
pound lesions involving a T,.T and a mismatch would occur
at a relatively high frequency (due to the abundance of
T,.T). Our data show that such lesions are excised about
fourfold faster than simple T,.T lesions by excision nuclease
and are bound hMutSa (and presumably processed) with
about twofold-lower affinity than a simple G-T mismatch. A
possible outcome would be the removal of the damaged bases
by excision nuclease before the removal of the mismatched
base by the mismatch repair system, and hence mutation fixa-
tion by excision repair (Fig. 9).
In addition to UV-induced mutations, the putative mutagen-
esis pathway presented in Fig. 9 is expected to contribute to
cisplatin-induced mutations as well, because a compound le-
sion of cisplatin 1,2-d(GpG) cross-link exhibits the same effect
on excision and mismatch repair systems as the T,.T com-
FIG. 8. Kinetics of excision of T,.T by reconstituted excision nuclease from a compound lesion with a 59 or 39G-T mismatch. (A) 59G-T mismatch. Excision levels
(as percentages of input substrate) were as follows: lane 1, not detectable; lane 2, 0.2; lane 3, 1.1; lane 4, 3.6; lane 5, 8.8; lanes 6 and 7, not detectable; lane 8, 0.1; lane
9, 0.6; and lane 10, 1.8. (B) 39 G-T mismatch. The excision levels as percentages were as follows: lanes 1 and 2, not detectable; lane 3, 0.1; lane 4, 4.1; lane 5, 8.5; lane
6, 13; lanes 7 to 10, not detectable; lane 11, 1.1; and lane 12, 3.3. Sizes are indicated in nucleotides.
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pound lesion. On the contrary, since T[6-4]T in a compound
lesion is not a better substrate than a simple T[6-4]T lesion,
and since T[6-4]T is a strong block to replication, the proposed
mutagenesis is not expected to play an important role in mu-
tations induced by T[6-4]T. The model in Fig. 9 predicts that
mutations at TT sequences which arise almost exclusively from
T,.T constitute a higher fraction of mutations in repair-
proficient cells than in repair-deficient cells. Indeed, a recent
study with a UV-irradiated shuttle vector found that wild-type
cells had a 12-fold increase in mutations at A-T pairs compared
to an xeroderma pigmentosum (XP) group A mutant, and a
literature survey of p53 mutations found in XP and non-XP
cancers revealed the same tendency (32). However, these con-
clusions are based on a relatively small data set. More studies
of this type are needed to solidify the proposed model.
Finally, the finding that compound lesions which destabilize
the helix are excised faster than the same lesions in an other-
wise base-paired duplex suggests that helix unwinding is on the
reaction path of human excision repair nuclease. Further re-
search using probes for DNA melting on DNA-protein com-
plexes formed with subassemblies of the excision nuclease is
needed to provide more definitive data on the structure of
DNA in the pre- and postincision excision nuclease complexes.
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